{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:17:43Z","timestamp":1788967063865,"version":"build-2803163510"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011198","name":"CAS \u00a6 State Key Laboratory of Drug Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073875"],"award-info":[{"award-number":["82073875"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773764"],"award-info":[{"award-number":["81773764"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073865"],"award-info":[{"award-number":["82073865"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SA\u2010SIBS Scholarship Program"},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["No.19QA1410900"],"award-info":[{"award-number":["No.19QA1410900"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Strategic Priority Research Program of the Chinese Academy of Sciences","award":["29201731121100101"],"award-info":[{"award-number":["29201731121100101"]}]},{"name":"The Strategic Priority Research Program of the Chinese Academy of Sciences","award":["XDA12010306"],"award-info":[{"award-number":["XDA12010306"]}]},{"name":"The Strategic Priority Research Program of the Chinese Academy of Sciences","award":["XDA12020104"],"award-info":[{"award-number":["XDA12020104"]}]},{"name":"The Strategic Priority Research Program of the Chinese Academy of Sciences","award":["XDA12020109"],"award-info":[{"award-number":["XDA12020109"]}]},{"name":"The Strategic Priority Research Program of the Chinese Academy of Sciences","award":["CASIMM0120185003"],"award-info":[{"award-number":["CASIMM0120185003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2023,3,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Poly\u2010ADP\u2010ribose polymerase (PARP) inhibitors (PARPi) have shown great promise for treating BRCA\u2010deficient tumors. However, over 40% of BRCA\u2010deficient patients fail to respond to PARPi. Here, we report that thioparib, a next\u2010generation PARPi with high affinity against multiple PARPs, including PARP1, PARP2, and PARP7, displays high antitumor activities against PARPi\u2010sensitive and \u2010resistant cells with homologous recombination (HR) deficiency both\n                    <jats:italic>in\u00a0vitro<\/jats:italic>\n                    and\n                    <jats:italic>in\u00a0vivo<\/jats:italic>\n                    . Thioparib treatment elicited PARP1\u2010dependent DNA damage and replication stress, causing S\u2010phase arrest and apoptosis. Conversely, thioparib strongly inhibited HR\u2010mediated DNA repair while increasing RAD51 foci formation. Notably, the on\u2010target inhibition of PARP7 by thioparib\u2010activated STING\/TBK1\u2010dependent phosphorylation of STAT1, triggered a strong induction of type I interferons (IFNs), and resulted in tumor growth retardation in an immunocompetent mouse model. However, the inhibitory effect of thioparib on tumor growth was more pronounced in PARP1 knockout mice, suggesting that a specific PARP7 inhibitor, rather than a pan inhibitor such as thioparib, would be more relevant for clinical applications. Finally, genome\u2010scale CRISPR screening identified\n                    <jats:italic>PARP1<\/jats:italic>\n                    and\n                    <jats:italic>MCRS1<\/jats:italic>\n                    as genes capable of modulating thioparib sensitivity. Taken together, thioparib, a next\u2010generation PARPi acting on both DNA damage response and antitumor immunity, serves as a therapeutic potential for treating hyperactive HR tumors, including those resistant to earlier\u2010generation PARPi.\n                  <\/jats:p>","DOI":"10.15252\/emmm.202216235","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T12:42:48Z","timestamp":1674045768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4269-0973","authenticated-orcid":false,"given":"Li\u2010Min","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-1755","authenticated-orcid":false,"given":"Xiao\u2010Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9489-9496","authenticated-orcid":false,"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan\u2010Shan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4681-0853","authenticated-orcid":false,"given":"Hua\u2010Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu\u2010Bin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1740-8913","authenticated-orcid":false,"given":"Ne","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia\u2010Juan","family":"Huan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan\u2010Yan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin\u2010Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi\u2010Ming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying\u2010Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2930-7781","authenticated-orcid":false,"given":"Jing\u2010Yu","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0833-6583","authenticated-orcid":false,"given":"Ze\u2010Hong","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7205-9202","authenticated-orcid":false,"given":"Ao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-5524","authenticated-orcid":false,"given":"Jin\u2010Xue","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"BFEMMM202216235_CR1","unstructured":"(2017) IDH\u2010mutant tumors vulnerable to PARP inhibition. Cancer Discov 7: OF4"},{"key":"BFEMMM202216235_CR3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-59074-4","volume":"10","author":"AA Antolin","year":"2020","unstructured":"Antolin AA, Ameratunga M, Banerji U, Clarke PA, Workman P, Al\u2010Lazikani B (2020) The kinase polypharmacology landscape of clinical PARP inhibitors. Sci Rep 10: 2585","journal-title":"Sci Rep"},{"key":"BFEMMM202216235_CR4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.euo.2020.07.005","volume":"3","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Gomella LG, Petrylak DP (2020) When and how to use PARP inhibitors in prostate cancer: a systematic review of the literature with an update on on\u2010going trials. Eur Urol Oncol 3: 594\u2013611","journal-title":"Eur Urol Oncol"},{"key":"BFEMMM202216235_CR5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2\u2010deficient tumours with inhibitors of poly(ADP\u2010ribose) polymerase. Nature 434: 913\u2013917","journal-title":"Nature"},{"key":"BFEMMM202216235_CR6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3390\/cells4040569","volume":"4","author":"M B\u00fctepage","year":"2015","unstructured":"B\u00fctepage M, Eckei L, Verheugd P, L\u00fcscher B (2015) Intracellular mono\u2010ADP\u2010ribosylation in signaling and disease. Cell 4: 569\u2013595","journal-title":"Cell"},{"key":"BFEMMM202216235_CR7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ijc.32131","volume":"145","author":"HD Chen","year":"2019","unstructured":"Chen HD, Chen CH, Wang YT, Guo N, Tian YN, Huan XJ, Song SS, He JX, Miao ZH (2019a) Increased PARP1\u2010DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1\u2010DNA trapping is correlated with PARP1 inhibitor's cytotoxicity. Int J Cancer 145: 714\u2013727","journal-title":"Int J Cancer"},{"key":"BFEMMM202216235_CR8","first-page":"8563","volume":"47","author":"Y Chen","year":"2019","unstructured":"Chen Y, Zhang H, Xu Z, Tang H, Geng A, Cai B, Su T, Shi J, Jiang C, Tian X et\u00a0al (2019b) A PARP1\u2010BRG1\u2010SIRT1 axis promotes HR repair by reducing nucleosome density at DNA damage sites. Nucleic Acids Res 47: 8563\u20138580","journal-title":"Nucleic Acids Res"},{"key":"BFEMMM202216235_CR9","first-page":"2813","volume":"10","author":"HD Chen","year":"2020","unstructured":"Chen HD, Guo N, Song SS, Chen CH, Miao ZH, He JX (2020a) Novel mutations in BRCA2 intron 11 and overexpression of COX\u20102 and BIRC3 mediate cellular resistance to PARP inhibitors. Am J Cancer Res 10: 2813\u20132831","journal-title":"Am J Cancer Res"},{"key":"BFEMMM202216235_CR10","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41419-020-03013-8","volume":"11","author":"X Chen","year":"2020","unstructured":"Chen X, Peng F, Ji Y, Xiang H, Wang X, Liu T, Wang H, Han Y, Wang C, Zhang Y et\u00a0al (2020b) Brca2 deficiency drives gastrointestinal tumor formation and is selectively inhibited by mitomycin C. Cell Death Dis 11: 812","journal-title":"Cell Death Dis"},{"key":"BFEMMM202216235_CR11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621\u2013681","journal-title":"Pharmacol Rev"},{"key":"BFEMMM202216235_CR12","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1038\/s41467-020-19961-w","volume":"11","author":"KE Clements","year":"2020","unstructured":"Clements KE, Schleicher EM, Thakar T, Hale A, Dhoonmoon A, Tolman NJ, Sharma A, Liang X, Imamura Kawasawa Y, Nicolae CM et\u00a0al (2020) Identification of regulators of poly\u2010ADP\u2010ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens. Nat Commun 11: 6118","journal-title":"Nat Commun"},{"key":"BFEMMM202216235_CR13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","volume":"29","author":"C Cruz","year":"2018","unstructured":"Cruz C, Castroviejo\u2010Bermejo M, Guti\u00e9rrez\u2010Enr\u00edquez S, Llop\u2010Guevara A, Ibrahim YH, Gris\u2010Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM et\u00a0al (2018) RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA\u2010mutated breast cancer. Ann Oncol 29: 1203\u20131210","journal-title":"Ann Oncol"},{"key":"BFEMMM202216235_CR14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin NJ, Szabo C (2020) Poly(ADP\u2010ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov 19: 711\u2013736","journal-title":"Nat Rev Drug Discov"},{"key":"BFEMMM202216235_CR15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias MP, Moser SC, Ganesan S, Jonkers J (2021) Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol 18: 773\u2013791","journal-title":"Nat Rev Clin Oncol"},{"key":"BFEMMM202216235_CR16","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH et\u00a0al (2018) PARP inhibition elicits STING\u2010dependent antitumor immunity in Brca1\u2010deficient ovarian cancer. Cell Rep 25: 2972\u20132980.e5","journal-title":"Cell Rep"},{"key":"BFEMMM202216235_CR17","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/nm.3993","volume":"21","author":"MT Esposito","year":"2015","unstructured":"Esposito MT, Zhao L, Fung TK, Rane JK, Wilson A, Martin N, Gil J, Leung AY, Ashworth A, So CW (2015) Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors. Nat Med 21: 1481\u20131490","journal-title":"Nat Med"},{"key":"BFEMMM202216235_CR18","volume":"8","author":"Y Fang","year":"2013","unstructured":"Fang Y, Zhong L, Lin M, Zhou X, Jing H, Ying M, Luo P, Yang B, He Q (2013) MEK\/ERK dependent activation of STAT1 mediates dasatinib\u2010induced differentiation of acute myeloid leukemia. PLoS One 8: e66915","journal-title":"PLoS One"},{"key":"BFEMMM202216235_CR19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.bbadis.2014.12.001","volume":"1852","author":"I Faraoni","year":"2015","unstructured":"Faraoni I, Compagnone M, Lavorgna S, Angelini DF, Cencioni MT, Piras E, Panetta P, Ottone T, Dolci S, Venditti A et\u00a0al (2015) BRCA1, PARP1 and gammaH2AX in acute myeloid leukemia: role as biomarkers of response to the PARP inhibitor olaparib. Biochim Biophys Acta 1852: 462\u2013472","journal-title":"Biochim Biophys Acta"},{"key":"BFEMMM202216235_CR20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C et\u00a0al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917\u2013921","journal-title":"Nature"},{"key":"BFEMMM202216235_CR21","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3324\/haematol.2012.079251","volume":"98","author":"TJ Gaymes","year":"2013","unstructured":"Gaymes TJ, Mohamedali AM, Patterson M, Matto N, Smith A, Kulasekararaj A, Chelliah R, Curtin N, Farzaneh F, Shall S et\u00a0al (2013) Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP\u2010ribose) polymerase inhibitors in myeloid malignancies. Haematologica 98: 1397\u20131406","journal-title":"Haematologica"},{"key":"BFEMMM202216235_CR22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.ccell.2021.06.018","volume":"39","author":"JM Gozgit","year":"2021","unstructured":"Gozgit JM, Vasbinder MM, Abo RP, Kunii K, Kuplast\u2010Barr KG, Gui B, Lu AZ, Molina JR, Minissale E, Swinger KK et\u00a0al (2021) PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Cancer Cell 39: 1214\u20131226.e10","journal-title":"Cancer Cell"},{"key":"BFEMMM202216235_CR23","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.18632\/oncotarget.13749","volume":"8","author":"JX He","year":"2017","unstructured":"He JX, Wang M, Huan XJ, Chen CH, Song SS, Wang YQ, Liao XM, Tan C, He Q, Tong LJ et\u00a0al (2017) Novel PARP1\/2 inhibitor mefuparib hydrochloride elicits potent in\u00a0vitro and in\u00a0vivo anticancer activity, characteristic of high tissue distribution. Oncotarget 8: 4156\u20134168","journal-title":"Oncotarget"},{"key":"BFEMMM202216235_CR24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","volume":"5","author":"T Helleday","year":"2011","unstructured":"Helleday T (2011) The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 5: 387\u2013393","journal-title":"Mol Oncol"},{"key":"BFEMMM202216235_CR25","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","volume":"13","author":"TA Hopkins","year":"2015","unstructured":"Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, DiGiammarino EL, Panchal SC, Wilsbacher JL, Gao W, Olson AM et\u00a0al (2015) Mechanistic dissection of PARP1 trapping and the impact on In vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res 13: 1465\u20131477","journal-title":"Mol Cancer Res"},{"key":"BFEMMM202216235_CR26","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/djy085","volume":"110","author":"MM Hoppe","year":"2018","unstructured":"Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD (2018) Biomarkers for homologous recombination deficiency in cancer. J Natl Cancer Inst 110: 704\u2013713","journal-title":"J Natl Cancer Inst"},{"key":"BFEMMM202216235_CR27","doi-asserted-by":"crossref","first-page":"22533","DOI":"10.1074\/jbc.M111.335331","volume":"287","author":"CC Hsu","year":"2012","unstructured":"Hsu CC, Lee YC, Yeh SH, Chen CH, Wu CC, Wang TY, Chen YN, Hung LY, Liu YW, Chen HK et\u00a0al (2012) 58\u2010kDa microspherule protein (MSP58) is novel Brahma\u2010related gene 1 (BRG1)\u2010associated protein that modulates p53\/p21 senescence pathway. J Biol Chem 287: 22533\u201322548","journal-title":"J Biol Chem"},{"key":"BFEMMM202216235_CR28","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1158\/1535-7163.MCT-13-0906-T","volume":"13","author":"P Jelinic","year":"2014","unstructured":"Jelinic P, Levine DA (2014) New insights into PARP inhibitors' effect on cell cycle and homology\u2010directed DNA damage repair. Mol Cancer Ther 13: 1645\u20131654","journal-title":"Mol Cancer Ther"},{"key":"BFEMMM202216235_CR29","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1021\/acs.jmedchem.1c01012","volume":"64","author":"JW Johannes","year":"2021","unstructured":"Johannes JW, Balazs A, Barratt D, Bista M, Chuba MD, Cosulich S, Critchlow SE, Degorce SL, Di Fruscia P, Edmondson SD et\u00a0al (2021) Discovery of 5\u2010{4\u2010[(7\u2010Ethyl\u20106\u2010oxo\u20105,6\u2010dihydro\u20101,5\u2010naphthyridin\u20103\u2010yl)methyl]piperazin\u20101\u2010yl}\u2010N\u2010methylpyridine\u20102\u2010carboxamide (AZD5305): a PARP1\u2010DNA trapper with high selectivity for PARP1 over PARP2 and other PARPs. J Med Chem 64: 14498\u201314512","journal-title":"J Med Chem"},{"key":"BFEMMM202216235_CR30","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.21873\/anticanres.14214","volume":"40","author":"A Kanellou","year":"2020","unstructured":"Kanellou A, Giakoumakis NN, Panagopoulos A, Tsaniras SC, Lygerou Z (2020) The licensing factor Cdt1 links cell cycle progression to the DNA damage response. Anticancer Res 40: 2449\u20132456","journal-title":"Anticancer Res"},{"key":"BFEMMM202216235_CR31","volume":"9","author":"C Kim","year":"2020","unstructured":"Kim C, Wang XD, Yu Y (2020) PARP1 inhibitors trigger innate immunity via PARP1 trapping\u2010induced DNA damage response. eLife 9: e60637","journal-title":"eLife"},{"key":"BFEMMM202216235_CR32","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, Irizarry RA, Liu JS, Brown M, Liu XS (2014) MAGeCK enables robust identification of essential genes from genome\u2010scale CRISPR\/Cas9 knockout screens. Genome Biol 15: 554","journal-title":"Genome Biol"},{"key":"BFEMMM202216235_CR33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13059-015-0843-6","volume":"16","author":"W Li","year":"2015","unstructured":"Li W, K\u00f6ster J, Xu H, Chen CH, Xiao T, Liu JS, Brown M, Liu XS (2015) Quality control, modeling, and visualization of CRISPR screens with MAGeCK\u2010VISPR. Genome Biol 16: 281","journal-title":"Genome Biol"},{"key":"BFEMMM202216235_CR34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J (2020) PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer 19: 107","journal-title":"Mol Cancer"},{"key":"BFEMMM202216235_CR35","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s10637-021-01096-4","volume":"39","author":"MZ Li","year":"2021","unstructured":"Li MZ, Meng T, Song SS, Bao XB, Ma LP, Zhang N, Yu T, Zhang YL, Xiong B, Shen JK et\u00a0al (2021) Discovery of MTR\u2010106 as a highly potent G\u2010quadruplex stabilizer for treating BRCA\u2010deficient cancers. Invest New Drugs 39: 1213\u20131221","journal-title":"Invest New Drugs"},{"key":"BFEMMM202216235_CR36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ebiom.2019.10.003","volume":"48","author":"T Liu","year":"2019","unstructured":"Liu T, Han Y, Yu C, Ji Y, Wang C, Chen X, Wang X, Shen J, Zhang Y, Lang JY (2019) MYC predetermines the sensitivity of gastrointestinal cancer to antifolate drugs through regulating TYMS transcription. EBioMedicine 48: 289\u2013300","journal-title":"EBioMedicine"},{"key":"BFEMMM202216235_CR37","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","volume":"23","author":"BH Lok","year":"2017","unstructured":"Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell SN et\u00a0al (2017) PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res 23: 523\u2013535","journal-title":"Clin Cancer Res"},{"key":"BFEMMM202216235_CR38","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord CJ, Ashworth A (2016) BRCAness revisited. Nat Rev Cancer 16: 110\u2013120","journal-title":"Nat Rev Cancer"},{"key":"BFEMMM202216235_CR39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1475-2867-12-46","volume":"12","author":"HI Lowe","year":"2012","unstructured":"Lowe HI, Watson CT, Badal S, Toyang NJ, Bryant J (2012) Cycloartane\u20103,24,25\u2010triol inhibits MRCKalpha kinase and demonstrates promising anti prostate cancer activity in\u00a0vitro. Cancer Cell Int 12: 46","journal-title":"Cancer Cell Int"},{"key":"BFEMMM202216235_CR40","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.21873\/anticanres.14286","volume":"40","author":"CB Machado","year":"2020","unstructured":"Machado CB, da Silva EL, de Moraes Filho MO, de Moraes MEA, Moreira\u2010Nunes CA (2020) PARP inhibitors as therapeutic options for tyrosine kinase\u2010dependent leukemia: a review. Anticancer Res 40: 3055\u20133063","journal-title":"Anticancer Res"},{"key":"BFEMMM202216235_CR41","doi-asserted-by":"crossref","first-page":"934","DOI":"10.4161\/cbt.4.9.2141","volume":"4","author":"N McCabe","year":"2005","unstructured":"McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A (2005) BRCA2\u2010deficient CAPAN\u20101 cells are extremely sensitive to the inhibition of poly (ADP\u2010ribose) polymerase: an issue of potency. Cancer Biol Ther 4: 934\u2013936","journal-title":"Cancer Biol Ther"},{"key":"BFEMMM202216235_CR42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cyto.2015.11.011","volume":"89","author":"K Meissl","year":"2017","unstructured":"Meissl K, Macho\u2010Maschler S, M\u00fcller M, Strobl B (2017) The good and the bad faces of STAT1 in solid tumours. Cytokine 89: 12\u201320","journal-title":"Cytokine"},{"key":"BFEMMM202216235_CR43","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/nar\/gkg034","volume":"31","author":"C von Mering","year":"2003","unstructured":"von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B (2003) STRING: a database of predicted functional associations between proteins. Nucleic Acids Res 31: 258\u2013261","journal-title":"Nucleic Acids Res"},{"key":"BFEMMM202216235_CR44","doi-asserted-by":"crossref","first-page":"784","DOI":"10.18632\/oncotarget.27485","volume":"11","author":"S Misra","year":"2020","unstructured":"Misra S, Zhang X, Wani NA, Sizemore S, Ray A (2020) Both BRCA1\u2010wild type and \u2010mutant triple\u2010negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment. Oncotarget 11: 784\u2013800","journal-title":"Oncotarget"},{"key":"BFEMMM202216235_CR45","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72: 5588\u20135599","journal-title":"Cancer Res"},{"key":"BFEMMM202216235_CR46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","volume":"13","author":"J Murai","year":"2014","unstructured":"Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y (2014) Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 13: 433\u2013443","journal-title":"Mol Cancer Ther"},{"key":"BFEMMM202216235_CR47","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou C, Sonzogni O, de Oliveira Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J, Castrillon JA et\u00a0al (2019) PARP inhibitor efficacy depends on CD8+ T cell recruitment via intratumoral STING pathway activation in BRCA\u2010deficient models of triple\u2010negative breast cancer. Cancer Discov 9: 722\u2013737","journal-title":"Cancer Discov"},{"key":"BFEMMM202216235_CR48","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ccell.2019.07.007","volume":"36","author":"S Parvin","year":"2019","unstructured":"Parvin S, Ramirez\u2010Labrada A, Aumann S, Lu X, Weich N, Santiago G, Cortizas EM, Sharabi E, Zhang Y, Sanchez\u2010Garcia I et\u00a0al (2019) LMO2 confers synthetic lethality to PARP inhibition in DLBCL. Cancer Cell 36: 237\u2013249.e6","journal-title":"Cancer Cell"},{"key":"BFEMMM202216235_CR49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.canlet.2016.11.021","volume":"386","author":"J Piao","year":"2017","unstructured":"Piao J, Takai S, Kamiya T, Inukai T, Sugita K, Ohyashiki K, Delia D, Masutani M, Mizutani S, Takagi M (2017) Poly (ADP\u2010ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3\u2010HLF\u2010positive leukemic cells. Cancer Lett 386: 131\u2013140","journal-title":"Cancer Lett"},{"key":"BFEMMM202216235_CR50","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1101\/gad.13.20.2633","volume":"13","author":"AJ Pierce","year":"1999","unstructured":"Pierce AJ, Johnson RD, Thompson LH, Jasin M (1999) XRCC3 promotes homology\u2010directed repair of DNA damage in mammalian cells. Genes Dev 13: 2633\u20132638","journal-title":"Genes Dev"},{"key":"BFEMMM202216235_CR51","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121979119","volume":"119","author":"J Rudolph","year":"2022","unstructured":"Rudolph J, Jung K, Luger K (2022) Inhibitors of PARP: number crunching and structure gazing. Proc Natl Acad Sci USA 119: e2121979119","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM202216235_CR52","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498\u20132504","journal-title":"Genome Res"},{"key":"BFEMMM202216235_CR53","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","volume":"19","author":"Y Shen","year":"2013","unstructured":"Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A (2013) BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 19: 5003\u20135015","journal-title":"Clin Cancer Res"},{"key":"BFEMMM202216235_CR54","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G (2019) PARPi triggers the STING\u2010dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res 79: 311\u2013319","journal-title":"Cancer Res"},{"key":"BFEMMM202216235_CR55","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3390\/biom2040635","volume":"2","author":"CE Str\u00f6m","year":"2012","unstructured":"Str\u00f6m CE, Helleday T (2012) Strategies for the use of poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors in cancer therapy. Biomolecules 2: 635\u2013649","journal-title":"Biomolecules"},{"key":"BFEMMM202216235_CR56","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2463","volume":"9","author":"PL Sulkowski","year":"2017","unstructured":"Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR et\u00a0al (2017) 2\u2010hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med 9: eaal2463","journal-title":"Sci Transl Med"},{"key":"BFEMMM202216235_CR57","doi-asserted-by":"crossref","first-page":"37080","DOI":"10.18632\/oncotarget.26354","volume":"9","author":"K Sun","year":"2018","unstructured":"Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G, Zhang ZY, Hanke J, Ramaswamy S, Wang J (2018) A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget 9: 37080\u201337096","journal-title":"Oncotarget"},{"key":"BFEMMM202216235_CR58","doi-asserted-by":"crossref","first-page":"7701","DOI":"10.18632\/oncotarget.6715","volume":"7","author":"J Wang","year":"2016","unstructured":"Wang J, Ding Q, Fujimori H, Motegi A, Miki Y, Masutani M (2016a) Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors. Oncotarget 7: 7701\u20137714","journal-title":"Oncotarget"},{"key":"BFEMMM202216235_CR59","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1021\/acs.jmedchem.6b00055","volume":"59","author":"YQ Wang","year":"2016","unstructured":"Wang YQ, Wang PY, Wang YT, Yang GF, Zhang A, Miao ZH (2016b) An update on poly(ADP\u2010ribose)polymerase\u20101 (PARP\u20101) inhibitors: opportunities and challenges in cancer therapy. J Med Chem 59: 9575\u20139598","journal-title":"J Med Chem"},{"key":"BFEMMM202216235_CR60","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/cas.13477","volume":"109","author":"YT Wang","year":"2018","unstructured":"Wang YT, Yuan B, Chen HD, Xu L, Tian YN, Zhang A, He JX, Miao ZH (2018) Acquired resistance of phosphatase and tensin homolog\u2010deficient cells to poly(ADP\u2010ribose) polymerase inhibitor and Ara\u2010C mediated by 53BP1 loss and SAMHD1 overexpression. Cancer Sci 109: 821\u2013831","journal-title":"Cancer Sci"},{"key":"BFEMMM202216235_CR61","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1038\/s41467-019-12606-7","volume":"10","author":"L Wei","year":"2019","unstructured":"Wei L, Lee D, Law CT, Zhang MS, Shen J, Chin DW, Zhang A, Tsang FH, Wong CL, Ng IO et\u00a0al (2019) Genome\u2010wide CRISPR\/Cas9 library screening identified PHGDH as a critical driver for sorafenib resistance in HCC. Nat Commun 10: 4681","journal-title":"Nat Commun"},{"key":"BFEMMM202216235_CR62","doi-asserted-by":"crossref","first-page":"428","DOI":"10.7150\/ijbs.5.428","volume":"5","author":"CD Wood","year":"2009","unstructured":"Wood CD, Thornton TM, Sabio G, Davis RA, Rincon M (2009) Nuclear localization of p38 MAPK in response to DNA damage. Int J Biol Sci 5: 428\u2013437","journal-title":"Int J Biol Sci"},{"key":"BFEMMM202216235_CR63","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12185-008-0199-8","volume":"88","author":"H Xiao","year":"2008","unstructured":"Xiao H, Zhang KJ, Xia B (2008) Defects of FA\/BRCA pathway in lymphoma cell lines. Int J Hematol 88: 543\u2013550","journal-title":"Int J Hematol"},{"key":"BFEMMM202216235_CR64","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/ni.3422","volume":"17","author":"T Yamada","year":"2016","unstructured":"Yamada T, Horimoto H, Kameyama T, Hayakawa S, Yamato H, Dazai M, Takada A, Kida H, Bott D, Zhou AC et\u00a0al (2016) Constitutive aryl hydrocarbon receptor signaling constrains type I interferon\u2010mediated antiviral innate defense. Nat Immunol 17: 687\u2013694","journal-title":"Nat Immunol"},{"key":"BFEMMM202216235_CR65","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/aps.2017.8","volume":"38","author":"ZM Yang","year":"2017","unstructured":"Yang ZM, Liao XM, Chen Y, Shen YY, Yang XY, Su Y, Sun YM, Gao YL, Ding J, Zhang A et\u00a0al (2017) Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP\u2010ribose) polymerase (PARP) inhibitors. Acta Pharmacol Sin 38: 1038\u20131047","journal-title":"Acta Pharmacol Sin"},{"key":"BFEMMM202216235_CR66","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1021\/jm301825t","volume":"56","author":"N Ye","year":"2013","unstructured":"Ye N, Chen CH, Chen T, Song Z, He JX, Huan XJ, Song SS, Liu Q, Chen Y, Ding J et\u00a0al (2013) Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin\u20107(8H)\u2010ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors. J Med Chem 56: 2885\u20132903","journal-title":"J Med Chem"},{"key":"BFEMMM202216235_CR67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2016.11.010","volume":"386","author":"B Yuan","year":"2017","unstructured":"Yuan B, Ye N, Song SS, Wang YT, Song Z, Chen HD, Chen CH, Huan XJ, Wang YQ, Su Y et\u00a0al (2017) Poly(ADP\u2010ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Cancer Lett 386: 47\u201356","journal-title":"Cancer Lett"},{"key":"BFEMMM202216235_CR68","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","volume":"12","author":"D Zatreanu","year":"2021","unstructured":"Zatreanu D, Robinson HMR, Alkhatib O, Boursier M, Finch H, Geo L, Grande D, Grinkevich V, Heald RA, Langdon S et\u00a0al (2021) Pol\u03b8 inhibitors elicit BRCA\u2010gene synthetic lethality and target PARP inhibitor resistance. Nat Commun 12: 3636","journal-title":"Nat Commun"},{"key":"BFEMMM202216235_CR69","unstructured":"Zhang A, Miao ZH, Wang PY, Huan XJ, Ding J (2015) Substituted triazolopyrazine PARP inhibitor, its preparation method and application. Chinese Patent CN201510818057.7. The United States Patent US10597399B2."},{"key":"BFEMMM202216235_CR70","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41419-021-03475-4","volume":"12","author":"N Zhang","year":"2021","unstructured":"Zhang N, Tian YN, Zhou LN, Li MZ, Chen HD, Song SS, Huan XJ, Bao XB, Zhang A, Miao ZH et\u00a0al (2021) Glycogen synthase kinase 3\u03b2 inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer. Cell Death Dis 12: 183","journal-title":"Cell Death Dis"},{"key":"BFEMMM202216235_CR71","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.exphem.2016.07.007","volume":"44","author":"L Zhao","year":"2016","unstructured":"Zhao L, So CW (2016) PARP\u2010inhibitor\u2010induced synthetic lethality for acute myeloid leukemia treatment. Exp Hematol 44: 902\u2013907","journal-title":"Exp Hematol"},{"key":"BFEMMM202216235_CR72","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK (2019) Metascape provides a biologist\u2010oriented resource for the analysis of systems\u2010level datasets. Nat Commun 10: 1523","journal-title":"Nat Commun"},{"key":"BFEMMM202216235_CR73","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","volume":"2","author":"J Zhou","year":"2021","unstructured":"Zhou J, Gelot C, Pantelidou C, Li A, Yucel H, Davis RE, Farkkila A, Kochupurakkal B, Syed A, Shapiro GI et\u00a0al (2021) A first\u2010in\u2010class polymerase theta inhibitor selectively targets homologous\u2010recombination\u2010deficient tumors. Nat Cancer 2: 598\u2013610","journal-title":"Nat Cancer"},{"key":"BFEMMM202216235_CR74","volume":"12","author":"H Zhu","year":"2021","unstructured":"Zhu H, Tang YD, Zhan G, Su C, Zheng C (2021) The critical role of PARPs in regulating innate immune responses. Front Immunol 12: 712556","journal-title":"Front Immunol"},{"key":"BFEMMM202216235_CR75","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41586-018-0291-z","volume":"559","author":"M Zimmermann","year":"2018","unstructured":"Zimmermann M, Murina O, Reijns MAM, Agathanggelou A, Challis R, Tarnauskait\u0117 \u017d, Muir M, Fluteau A, Aregger M, McEwan A et\u00a0al (2018) CRISPR screens identify genomic ribonucleotides as a source of PARP\u2010trapping lesions. Nature 559: 285\u2013289","journal-title":"Nature"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.202216235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.15252\/emmm.202216235","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.15252\/emmm.202216235\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.15252\/emmm.202216235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.202216235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:48:06Z","timestamp":1779086886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.15252\/emmm.202216235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,8]]}},"alternative-id":["BFEMMM202216235"],"URL":"https:\/\/doi.org\/10.15252\/emmm.202216235","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"29 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"EMMM202216235"}}